Trial · NCT07602062
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse events at 6 months | From enrollment to the end of treatment at 6 months | Within 6 months, the time from randomization to the first occurrence of any of the following events: including gastrointestinal bleeding, new onset or worsening of ascites \> grade II, new onset or worsening of portal vein thrombosis, treatment with interventional transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation, and occurrence of death. |
| Secondary | Adverse events at 1months | From enrollment to 1months of treatment | Gastrointestinal bleeding, new or aggravated ascites \> Grade II, new or aggravated portal vein thrombosis, treatment with interventional transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation, death |
| Secondary | Adverse events at 2 months | From enrollment to the 2 months of treatment | Gastrointestinal bleeding, new or aggravated ascites \> Grade II, new or aggravated portal vein thrombosis, treatment with interventional transjugular intrahepatic portosystemic shunt (TIPS) or liver transplantation, death |
| Secondary | liver function at 6 months of treatment | From the enrollment to 6 months of treatment | Changes in liver function at 6 months of treatment measured by ALT/AST/Total Bilirubin level |
| Secondary | renal function at 6 months of treatment | From the enrollment to 6 months of treatment | Changes in renal function at 6 months of treatment measured by serum creatinine level |
| Secondary | Hemodynamic changes at 6 months | From enrollment to the end of treatment at 6 months | flow velocity of the portal vein system (m/s) measured by ultrasound |
| Secondary | Patency of portal vein thrombosis at 6 months | From enrollment to the end of treatment at 6 months | changes of portal vein thrombosis measured by CT Venography at 6 months (progress or recanalization） |
| Secondary | liver stiffness at 6 months | From enrollment to the end of treatment at 6 months | liver stiffness after 6 months of treatment measured by fibroscan |
| Secondary | spleen stiffness at 6 months | From enrollment to the end of treatment at 6 months | spleen stiffness after 6 months of treatment measured by fibroscan. |
| Secondary | Rivaroxaban Plasma Concentration at 6 Months | From enrollment to the end of treatment at 6 months | Changes in Rivaroxaban Plasma Concentration After 6 Months of Treatment |
| Secondary | Serum metabolomics at 6 months | From enrollment to the end of treatment at 6 months | metabolomic analysis of the patients' serum after treatment for 6 months using Liquid Chromatography-Mass Spectrometry (LC-MS) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07602062/registered